Sustained Improvements in Depression with CBPMs – Insights from the UK Medical Cannabis Registry – 2026

By /

A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.

Fresh evidence from the UK Medical Cannabis Registry highlights promising long-term outcomes for patients with depression using prescribed cannabis-based products for medicinal use (CBPMs). Published on 6 January 2026 in the Journal of Affective Disorders, this two-year case series analyzed data from 698 patients, showing sustained and clinically meaningful improvements in mood, anxiety, sleep quality, and overall health-related quality of life.

This observational study (the largest of its kind in the UK) tracked patients prescribed CBMPs for depression—many with treatment-resistant cases where conventional options had limited success. Over 24 months:

  • Significant reductions in depression symptoms (measured via validated patient-reported outcome measures like GAD-7 for anxiety and PHQ-9 equivalents).
  • Improvements in anxiety, sleep disturbance, and daily functioning.
  • Health-related quality of life showed ongoing gains, not just short-term relief.
  • Adverse events were mostly mild (e.g., dry mouth, fatigue), with low discontinuation rates—supporting a favorable safety profile in real-world use.

Researchers noted these changes were “clinically meaningful” and persisted across the full two years, adding to growing registry evidence that individualized CBMP prescribing (oils, flower, balanced THC/CBD ratios) can help where other treatments fall short. It’s not a randomized trial, so causation isn’t proven—but as real-world data from UK patients, it’s highly relevant.

For UK medicinal patients — This reinforces why specialists consider CBPMs for depression/anxiety when guidelines allow (e.g., after failing standard therapies). Dosing remains personalized—often starting low with CBD-dominant products before adding THC. Always under GMC-registered clinician supervision; never self-medicate.

This study builds on prior registry insights (e.g., for anxiety, PTSD) and underscores the value of ongoing data collection as access evolves.

What do you think? Have registry studies influenced your discussions with clinicians, or experiences with CBPMs for mood? Comment below!

Sources (January 2026):

Scroll to Top